title: Emergence of broadly neutralizing antibodies and viral coevolution in two subjects during the early stages of infection with human immunodeficiency virus type 1.
abstract: Delineating the key early events that lead to the development of broadly neutralizing anti-HIV-1 antibodies during natural infection may help guide the development of immunogens and vaccine regimens to prevent HIV-1 infection. In this study, we monitored two HIV-1-positive subjects, VC20013 and VC10014, over the course of infection from before they developed broadly neutralizing antibody (bNAb) activity until several years after neutralizing breadth was detected in plasma. Both subjects developed bNAb activity after approximately 1 year postinfection, which ultimately mapped to the membrane-proximal external region (MPER) in VC20013 and an epitope that overlaps the CD4 receptor binding site in VC10014. In subject VC20013, we were able to identify anti-MPER activity in the earliest plasma sample that exhibited no bNAb activity, indicating that this epitope specificity was acquired very early on, but that it was initially not able to mediate neutralization. Escape mutations within the bNAb epitopes did not arise in the circulating envelopes until bNAb activity was detectable in plasma, indicating that this early response was not sufficient to drive viral escape. As bNAb activity began to emerge in both subjects, we observed a simultaneous increase in autologous antienvelope antibody binding affinity, indicating that antibody maturation was occurring as breadth was developing. Our findings illustrate one potential mechanism by which bNAbs develop during natural infection in which an epitope target is acquired very early on during the course of infection but require time and maturation to develop into broadly neutralizing activity.
  
  
  OBJECTIVE
  One major goal of HIV-1 vaccine research is the development of a vaccine that can elicit broadly neutralizing antibodies (bNAbs). Although no such vaccine exists, bNAbs develop in approximately 20% of HIV-1-infected subjects, providing a prototype of the bNAbs that must be reelicited by vaccine. Thus, there is significant interest in understanding the mechanisms by which bNAbs develop during the course of infection. We studied the timing, epitope specificity, and evolution of the bNAb responses in two HIV-1-positive patients who developed bNAb activity within the first several years after infection. In one subject, antibodies to a broadly neutralizing epitope developed very early but were nonneutralizing. After several months, neutralizing activity developed, and the virus mutated to escape their activity. Our study highlights one mechanism for the development of bNAbs where early epitope acquisition followed by sufficient time for antibody maturation drives the epitope-specific antibody response toward broadly neutralizing activity.
authors.affiliation: Seattle Biomedical Research Institute, Seattle, Washington, USA noah.sather@seattlebiomed.org Leo.stamatatos@seattlebiomed.org.
authors.forename: D Noah
authors.initials: DN
authors.lastname: Sather
authors.affiliation: Seattle Biomedical Research Institute, Seattle, Washington, USA.
authors.forename: Sara
authors.initials: S
authors.lastname: Carbonetti
authors.affiliation: Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA.
authors.forename: Delphine C
authors.initials: DC
authors.lastname: Malherbe
authors.affiliation: Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA.
authors.forename: Franco
authors.initials: F
authors.lastname: Pissani
authors.affiliation: Seattle Biomedical Research Institute, Seattle, Washington, USA.
authors.forename: Andrew B
authors.initials: AB
authors.lastname: Stuart
authors.affiliation: Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA.
authors.forename: Ann J
authors.initials: AJ
authors.lastname: Hessell
authors.affiliation: Seattle Biomedical Research Institute, Seattle, Washington, USA.
authors.forename: Mathew D
authors.initials: MD
authors.lastname: Gray
authors.affiliation: Seattle Biomedical Research Institute, Seattle, Washington, USA.
authors.forename: Iliyana
authors.initials: I
authors.lastname: Mikell
authors.affiliation: Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
authors.forename: Spyros A
authors.initials: SA
authors.lastname: Kalams
authors.affiliation: Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA.
authors.forename: Nancy L
authors.initials: NL
authors.lastname: Haigwood
authors.affiliation: Seattle Biomedical Research Institute, Seattle, Washington, USA Department of Global Health, University of Washington, Seattle, Washington, USA noah.sather@seattlebiomed.org Leo.stamatatos@seattlebiomed.org.
authors.forename: Leonidas
authors.initials: L
authors.lastname: Stamatatos
mesh_terms: D057134:Antibodies, Neutralizing / Q000097:blood*; D000939:Epitopes / Q000276:immunology; D015483:HIV Antibodies / Q000097:blood*; D015658:HIV Infections / Q000276:immunology* / Q000821:virology*; D015497:HIV-1 / Q000276:immunology* / Q000302:isolation & purification; D006801:Humans; D013997:Time Factors
chemical_list: D057134:Antibodies, Neutralizing; D000939:Epitopes; D015483:HIV Antibodies